DNDi is pleased to announce the appointment of Mark Sullivan to the organization’s Scientific Advisory Committee.
Mark Sullivan is a clinical and regulatory scientist with significant experience in the development of new medicines for infectious diseases. He is the founder, CEO, and Managing Director of Medicines Development for Global Health (MDGH), an independent not-for-profit organisation dedicated to the development of medicines for diseases disproportionately affecting low- and middle-income countries. Under his project leadership, MDGH obtained United States Food and Drug Administration (US FDA) approval of moxidectin for the treatment of river blindness in 2018 – the first new treatment for the neglected tropical disease receiving regulatory approval in the US in 20 years and worldwide in 30 years.
Mark Sullivan has experience leading global cross functional project teams and regulatory interactions, and has either run, or had responsibility for, over a hundred clinical trials at all stages of drug development. He has broad therapeutic experience in infectious diseases, particularly hepatitis B, hepatitis C, HIV, onchocerciasis, lymphatic filariasis, scabies, soil transmitted helminths, leprosy, and tuberculosis.
Mark Sullivan is an Honorary Professor at the University of New South Wales and an Officer of the Order of Australia.
‘DNDi has long been the role model in finding solutions to diseases that affect the world’s most disadvantaged communities. For many years, I have watched and admired the organisation from afar and share their passion to improve peoples’ lives through better medicines. It is an honour to serve DNDi’s fantastic team and communities as part of the Scientific Advisory Committee.‘
Mark Sullivan
The DNDi Scientific Advisory Committee provides independent and exclusively evidence-driven recommendations to the Board of Directors on matters related to research and development and choice of projects. The Committee is composed of prominent scientists with drug discovery and development expertise, as well as medical and public health experts with disease-specific expertise or expertise with specific neglected populations. More information
